Abstract:Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders. Voltage-gated sodium channels (Na V s) are responsible for action potential initiation and transmission of pain signals. Na V 1.8 is specifically expressed in peripheral nociceptors and has been genetically and pharmacologically validated as a human pain target. Selective inhibition of Na V 1.8 can ameliorate pain while minimizing effects on other Na V isoforms essential for cardiac, respiratory, and central nervous system physiology. Here we present the pharmacology, interaction site, and mechanism of action of LTGO-33, a novel Na V 1.8 small molecule inhibitor. LTGO-33 inhibited Na V 1.8 in the nM potency range and exhibited over 600-fold selectivity against human Na V 1.1–Na V 1.7 and Na V 1.9. Unlike prior reported Na V 1.8 inhibitors that preferentially interacted with an inactivated state via the pore region, LTGO-33 was state-independent with similar potencies against closed and inactivated channels. LTGO-33 displayed species specificity for primate Na V 1.8 over dog and rodent Na V 1.8 and inhibited action potential firing in human dorsal root ganglia neurons. Using chimeras combined with mutagenesis, the extracellular cleft of the second voltage-sensing domain was identified as the key site required for channel inhibition. Biophysical mechanism of action studies demonstrated that LTGO-33 inhibition was relieved by membrane depolarization, suggesting the molecule stabilized the deactivated state to prevent channel opening. LTGO-33 equally inhibited wild-type and multiple Na V 1.8 variants associated with human pain disorders. These collective results illustrate LTGO-33 inhibition via both a novel interaction site and mechanism of action previously undescribed in Na V 1.8 small molecule pharmacologic space. SIGNIFICANCE STATEMENT Na V 1.8 sodium channels primarily expressed in peripheral pain-sensing neurons represent a validated target for the development of novel analgesics. Here we present the selective small molecule Na V 1.8 inhibitor LTGO-33 that interdicts a distinct site in a voltage-sensor domain to inhibit channel opening. These results inform the development of new analgesics for pain disorders.

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

Small Interfering RNA-mediated Selective Knockdown of NaV1.8 Tetrodotoxin-Resistant Sodium Channel Reverses Mechanical Allodynia in Neuropathic Rats

Structural basis for high-voltage activation and subtype-specific inhibition of human Na v 1.8.

Discovery of selective Na V 1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Structural basis for high-voltage activation and subtype-specific inhibition of human Na<sub>v</sub>1.8

Discovery of Selective NaV1.8 Inhibitors Based on 5-Chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl Nicotinamide Scaffold for the Treatment of Pain

Structural basis for Na V 1.7 inhibition by pore blockers

Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Structural and Functional Characterization of a Novel Scorpion Toxin that Inhibits NaV1.8 via Interactions With the DI Voltage Sensor and DII Pore Module

The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state

A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

Discovery of E0199: A Novel Compound Targeting Both Peripheral NaV and KV7 Channels to Alleviate Neuropathic Pain

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

Analgesic potential of voltage gated sodium channel modulators for the management of pain

Sodium Channel Inhibitors (Nav1.7, 1.8, And 1.9) For Neuropathic Pain Management

Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain

ST‐2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non‐human primates

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel